Allopregnanolone Levels are Inversely Associated with Self-Reported Pain Symptoms in U.S.Iraq and Afghanistan-Era Veterans: Implications for Biomarkers and Therapeutics
Author(s) -
Jennifer C. Naylor,
Jason D. Kilts,
Steven T. Szabo,
Charlotte Dunn,
Francis J. Keefe,
Larry A. Tupler,
Lawrence J. Shampine,
Rajendra A. Morey,
Jennifer L. Strauss,
Robert M. Hamer,
Henry R. Wagner,
Christine E. Marx
Publication year - 2015
Publication title -
pain medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.893
H-Index - 97
eISSN - 1526-4637
pISSN - 1526-2375
DOI - 10.1111/pme.12860
Subject(s) - allopregnanolone , medicine , neuroactive steroid , analgesic , pain medicine , biomarker , anesthesia , anesthesiology , gabaa receptor , biochemistry , chemistry , receptor
Pain symptoms are common among Iraq/Afghanistan-era veterans, many of whom continue to experience persistent pain symptoms despite multiple pharmacological interventions. Preclinical data suggest that neurosteroids such as allopregnanolone demonstrate pronounced analgesic properties, and thus represent logical biomarker candidates and therapeutic targets for pain. Allopregnanolone is also a positive GABAA receptor modulator with anxiolytic, anticonvulsant, and neuroprotective actions in rodent models. We previously reported inverse associations between serum allopregnanolone levels and self-reported pain symptom severity in a pilot study of 82 male veterans.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom